FUSN vs. TARS, YMAB, PGNX, MGTX, EXEL, RVMD, HALO, CRSP, KRYS, and IBRX
Should you be buying Fusion Pharmaceuticals stock or one of its competitors? The main competitors of Fusion Pharmaceuticals include Tarsus Pharmaceuticals (TARS), Y-mAbs Therapeutics (YMAB), Progenics Pharmaceuticals (PGNX), MeiraGTx (MGTX), Exelixis (EXEL), Revolution Medicines (RVMD), Halozyme Therapeutics (HALO), CRISPR Therapeutics (CRSP), Krystal Biotech (KRYS), and ImmunityBio (IBRX). These companies are all part of the "medical" sector.
Fusion Pharmaceuticals (NASDAQ:FUSN) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, community ranking, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.
Fusion Pharmaceuticals has a beta of -0.69, indicating that its stock price is 169% less volatile than the S&P 500. Comparatively, Tarsus Pharmaceuticals has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500.
72.9% of Fusion Pharmaceuticals shares are owned by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 7.8% of Fusion Pharmaceuticals shares are owned by insiders. Comparatively, 8.3% of Tarsus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Tarsus Pharmaceuticals received 1 more outperform votes than Fusion Pharmaceuticals when rated by MarketBeat users. Likewise, 64.62% of users gave Tarsus Pharmaceuticals an outperform vote while only 64.06% of users gave Fusion Pharmaceuticals an outperform vote.
Fusion Pharmaceuticals has higher earnings, but lower revenue than Tarsus Pharmaceuticals. Fusion Pharmaceuticals is trading at a lower price-to-earnings ratio than Tarsus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Tarsus Pharmaceuticals had 2 more articles in the media than Fusion Pharmaceuticals. MarketBeat recorded 5 mentions for Tarsus Pharmaceuticals and 3 mentions for Fusion Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 0.62 beat Fusion Pharmaceuticals' score of 0.31 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media.
Fusion Pharmaceuticals presently has a consensus target price of $20.25, indicating a potential downside of 6.03%. Tarsus Pharmaceuticals has a consensus target price of $50.38, indicating a potential upside of 56.44%. Given Tarsus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Tarsus Pharmaceuticals is more favorable than Fusion Pharmaceuticals.
Tarsus Pharmaceuticals has a net margin of 0.00% compared to Fusion Pharmaceuticals' net margin of -4,136.55%. Fusion Pharmaceuticals' return on equity of -48.74% beat Tarsus Pharmaceuticals' return on equity.
Summary
Tarsus Pharmaceuticals beats Fusion Pharmaceuticals on 13 of the 18 factors compared between the two stocks.
Get Fusion Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for FUSN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FUSN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fusion Pharmaceuticals Competitors List
Related Companies and Tools
